| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
7,188 |
6,500 |
$680K |
| S9083 |
Global fee urgent care centers |
3,399 |
2,531 |
$356K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,930 |
2,516 |
$267K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
3,483 |
2,755 |
$201K |
| 87428 |
|
3,185 |
2,873 |
$170K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
4,700 |
4,146 |
$144K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,303 |
2,134 |
$89K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,147 |
957 |
$59K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
1,286 |
1,124 |
$28K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
477 |
436 |
$26K |
| 99423 |
|
389 |
344 |
$17K |
| 99358 |
Prolong nursin fac eval 15m |
540 |
429 |
$14K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
52 |
45 |
$13K |
| 99205 |
Prolong outpt/office vis |
129 |
119 |
$13K |
| 99441 |
|
367 |
309 |
$7K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
84 |
81 |
$7K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
439 |
403 |
$5K |
| M0245 |
Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring |
39 |
35 |
$4K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
28 |
26 |
$3K |
| M0244 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency |
16 |
14 |
$3K |
| 99215 |
Prolong outpt/office vis |
15 |
14 |
$1K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
14 |
14 |
$1K |
| 99417 |
Prolong home eval add 15m |
89 |
84 |
$933.92 |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
57 |
44 |
$751.68 |
| 36000 |
|
94 |
89 |
$705.62 |
| 99350 |
Prolong home eval add 15m |
15 |
13 |
$460.00 |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
13 |
13 |
$68.90 |
| INVCD |
|
63 |
54 |
$0.00 |